Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis

Journal of Infection

Volumn 59, Issue 2, 2009, Pages 139-143

  Ajdary, Soheila ^a   Riazi Rad, Farhad ^a   Alimohammadian, Mohammad Hossein ^a   Pakzad, Saeed Reza ^b  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Immune response; Leishmania tropica; Non healing patients

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 5; PARASITE ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CELL CULTURE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GIEMSA STAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE STATUS; IRAN; LEISHMANIA TROPICA; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; SCHOOL CHILD; SKIN CULTURE; SKIN LEISHMANIASIS; SKIN TEST; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, PROTOZOAN; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CYTOKINES; FEMALE; HUMANS; IRAN; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 67949091021     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.05.010     Document Type: Article

References (34)

1. Klaus S., and Frankenburg Sh. Cutaneous leishmaniasis in the Middle East. Clin Dermatol 17 (1999) 137-141
2. Salman S.M., Rubeiz N.G., and Kibbi A. Cutaneous leishmaniasis: clinical features and diagnosis. Clin Dermatol 17 (1999) 291-296
3. Momeni A.Z., and Aminjavaheri M. Clinical picture of cutaneous leishmaniasis in Isfahan. Iran. Int J Dermatol 33 (1994) 260-265
4. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 14 (1996) 425-431
5. Magill A.J., Grogl M., Gasser R.A., Sun W., and Oster C.N. Visceral infection caused by Leishmania tropica in veterans of operation desert storm. N Engl J Med 328 (1993) 1383-1387
6. Alborzi A., Rasouli M., and Shamsizadeh A. Leishmania tropica-isolated patient with visceral leishmaniasis in southern Iran. Am J Trop Med Hyg 74 (2006) 306-307
7. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2 (2002) 845-858
8. Lira R., Mendez S., Carrera L., Ch J., and Neva F. Leishmania tropica: the identification and purification of metacyclic promastigotes and use in establishing mouse and hamster models of cutaneous and visceral disease. Exp Parasitol 89 (1998) 331-342
9. Jones D.E., Ackermann M.R., Wille U., Hunter C.A., and Scott Ph. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun 70 (2002) 2151-2158
10. Bogdan C., and Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 28 (1998) 121-134
11. Sacks D., and Anderson C.H. Re-examination of the immunosuppressive mechanisms mediating non-cure of leishmania infection in mice. Immunol Rev 201 (2004) 225-238
12. Reiner S., and Locksley R. The regulation of immunity to Leishmania major. Annu Rev Immunol 13 (1995) 151-177
13. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., and Locksley R.M. Reciprocal expression of interferon gamma or interleukin-4 during the resolution or progression of murine leishmaniasis, evidence for expansion of distinct helper T cell subsets. J Exp Med 169 (1989) 59-72
14. Kane M.M., and Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166 (2001) 1141-1147
15. Matthews D.J., Emson C.L., McKenzie G.J., Jolin H.E., Blackwell J.M., and McKenzie A.N.J. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 164 (2000) 1458-1462
16. Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26 (1996) 1553-1559
17. Pinheiro R.O., and Rossi-Bergmann B. Interferon-gamma is required for the late, but not early control of Leishmania amazonensis infection in C57BL/6 mice. Mem Inst Oswaldo Cruz 102 (2007) 79-82
18. Buxbaum L.U., Uzonna J.E., Goldschmidt M.H., and Scott P. Control of New World cutaneous leishmaniasis is IL-12-independent, but STAT4 dependent. Eur J Immunol 32 (2002) 3206-3215
19. Anderson C.H., Lira R., Kamhawi S., Belkaid Y., Wynn T., and Sacks D. IL-10 and TGF-β control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J Immunol 180 (2008) 4090-4097
20. Hatam G.R., Hosseini S.M., and Ardehali S. Dermotropic isolates of Leishmania infantum in Iran. Trans R Soc Trop Med Hyg 91 (1997) 440
21. Ajdary S., Alimohammadian M.H., Eslami M.B., Kemp K., and Kharazmi A. Comparison of the immune profile of non-healing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 68 (2000) 1760-1764
22. Convit J., Ulrich M., Fernandez C.T., Tapia F.J., Caceres-Dittmar G., Castes M., et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87 (1993) 444-448
23. Follador I., Araújo C., Bacellar O., Araújo C.B., Carvalho L.P., Almeida R.P., et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 34 (2002) 54-58
24. Leopoldo P.T., Machado P.R., Almeida R.P., Schriefer A., Giudice A., de Jesus A.R., et al. Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production. BMC Infect Dis 6 (2006) 75 10.1186/1471-2334-6-75
25. Gaafar A., Kharazmi A., Ismail A., Kemp M., Hey A., Christensen C.B.V., et al. Dichotomy of T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis: absence or scarcity of Th1 activity is associated with severe infections. Clin Exp Immunol 100 (1995) 239-245
26. Kemp K., Theander T.G., Hviid L., Gaafar A., Kharazmi A., and Kemp M. IFN-γ and TNF-α producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol 49 (1999) 655-659
27. Coutinho S.G., Oliveira M.P., Da-Cruz A.M., De-Luca P.M., Mendonça S.C.F., Bertho A.L., et al. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens. Immunologic patterns associated with cure. Exp Parasitol 84 (1996) 144-155
28. Da-Cruz A.M., Bittar R., Mattos M., Oliveira-Neto M.P., Nogueira R., Pinho-Ribeiro V., et al. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin Diagn Lab Immunol 9 (2002) 251-256
29. Bittar R.C., Nogueira R.S., Vieira-Gonçalves R., Pinho-Ribeiro V., Mattos M.S., Oliveira-Neto M.P., et al. T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz 102 (2007) 625-630
30. de Waal Malefyt R., Figdor C., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype cytokine production and cytotoxic function of human macrophages. J Immunol 151 (1993) 6370-6381
31. Minty A., Chalon P., Derocq J.M., Dumont X., Guillemot J.C., Kaghad M., et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362 (1993) 248-250
32. Noben-Trauth N., Paul W.E., and Sacks D.L. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol 162 (1999) 6132-6140
33. Bourreau E., Prevot G., Pradinaud R., and Launois P. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4 + T cells unresponsive to IL-12. J Infect Dis 183 (2001) 953-959
34. Mohrs M., Ledermann B., Kohler G., Dorfmuller A., Gessuer A., and Brombacher F. Differences between IL-4 and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 162 (1999) 7302-7308